Comparison of gal and non-gal-mediated cardiac xenograft rejection

Transplantation

Volumn 91, Issue 9, 2011, Pages 968-975

  Tazelaar, Henry D ^a,b   Byrne, Guerard W ^b,c   McGregor, Christopher G A ^b,c  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antibody; Cardiac; Rejection; Transplant; Xenotransplant

Indexed keywords

ANTIBODY; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C5B; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GALACTOSAMINE; GALACTOSAMINE ANTIBODY; POLYMER; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; BABOON; BLEEDING; CARDIAC GRAFT REJECTION; CELL VACUOLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; GRAFT RECIPIENT; HEART EDEMA; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE NECROSIS; HISTOPATHOLOGY; HYPERACUTE GRAFT REJECTION; MICROANGIOPATHY; NONHUMAN; PRIORITY JOURNAL; SWINE; THROMBOSIS; XENOGRAFT;

ANIMALS; ANTIBODIES, HETEROPHILE; GALACTOSYLTRANSFERASES; GENE KNOCKOUT TECHNIQUES; GRAFT REJECTION; HEART TRANSPLANTATION; MICROVESSELS; MYOCYTES, CARDIAC; NECROSIS; PAPIO; SWINE; THROMBOSIS; TRANSPLANTATION, HETEROLOGOUS; TRISACCHARIDES;

EID: 79955536634     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318212c7fe     Document Type: Article

References (38)

1. Platt JL, Lin SS, McGregor CGA. Acute vascular rejection. Xenotransplantation 1998; 5: 169.
2. Platt JL, Fischel RJ, Matas AJ, et al. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991; 52: 214.
3. Schuurman H-J, Cheng J, Lam T. Pathology of xenograft rejection: A commentary. Xenotransplantation 2003; 10: 293.
4. Weisman HF, Bartow T, Leppo MK, et al. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing postischemic myocardial inflammation and necrosis. Science 1990; 249: 146.
5. Miyagawa S, Hirose H, Shirakura R, et al. The mechanism of discordant xenograft rejection. Transplantation 1988; 46: 825.
6. Kozlowski T, Ierino FL, Lambrigts D, et al. Depletion of anti- Gal 1-3Gal antibody in baboons by specific- Gal immunoaffinity columns. Xenotransplantation 1998; 5: 122.
7. Byrne GW, McCurry KR, Martin MJ, et al. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage. Transplantation 1997; 63: 149.
8. Rose AG, Cooper DKC. Venular thrombosis is the key event in the pathogenesis of antibody-mediated cardiac rejection. Xenotransplantation 2000; 7: 31.
9. Kopp CW, Siegel JB, Hancock WW, et al. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors. Transplantation 1997; 63: 749.
10. Siegel JB, Grey ST, Lesnikoski BA, et al. Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997; 64: 888.
11. Mazzucato M, DeMarco L, Pradella P, et al. Porcine von Willebrand factor binding to human platelet GPIb induces transmembrane calcium influx. Thromb Haemost 1996; 75: 655.
12. Byrne GW, Schwarz A, Fesi JR, et al. Evaluation of different alpha- Galactosyl glycoconjugates for use in xenotransplantation. Bioconjug Chem 2002; 13: 571.
13. Katopodis AG, Warner RG, Duthaler RO, et al. Removal of anti-Gal 1,3Gal xenoantibodies with an injectable polymer. J Clin Invest 2002; 110: 1869.
14. Lai L, Kolber-Simonds D, Park K-W, et al. Production of -1,3- galactosyltransferase knockout pigs by nuclear transfer cloning. Science 2002; 295: 1089.
15. Phelps CJ, Koike C, Vaught TD, et al. Production of alpha 1,3- galactosyltransferase-deficient pigs. Science 2003; 299: 411.
16. Kuwaki K, Knosalla C, Dor FJ, et al. Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human anti-human CD154 mAb-based regimen. Am J Transplant 2004; 4: 363.
17. Kuwaki K, Tseng YL, Dor FJ, et al. Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: Initial experience. Nat Med 2005; 11: 29.
18. McGregor CG, Davies WR, Oi K, et al. Cardiac xenotransplantation: Recent preclinical progress with 3-month median survival. J Thorac Cardiovasc Surg 2005; 130: 844.
19. McGregor CG, Teotia SS, Byrne GW, et al. Cardiac xenotransplantation: Progress toward the clinic. Transplantation 2004; 78: 1569.
20. Chen G, Qian H, Starzl T, et al. Acute rejection is associated with antibodies to non-Gal antigens in baboons using Gal-knockout pig kidneys. Nat Med 2005; 11: 1295.
21. Byrne GW, Schirmer JM, Fass DN, et al. Warfarin or low-molecularweight heparin therapy does not prolong pig-to-primate cardiac xenograft function. Am J Transplant 2005; 5: 1011.
22. Shimizu A, Hisashi Y, Kuwaki K, et al. Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha1,3- galactosyltransferase gene-knockout pigs in baboons. Am J Pathol 2008; 172: 1471.
23. Ezzelarab M, Hara H, Busch J, et al. Antibodies directed to pig non-Gal antigens in naive and sensitized baboons. Xenotransplantation 2006; 13: 400.
24. Byrne GW, Stalboerger PG, Davila E, et al. Proteomic identification of non-Gal antibody targets after pig-to-primate cardiac xenotransplantation. Xenotransplantation 2008; 15: 268.
25. Tseng YL, Moran K, Dor FJ, et al. Elicited antibodies in baboons exposed to tissues from alpha1,3-galactosyltransferase gene-knockout pigs. Transplantation 2006; 81: 1058.
26. Schmoeckel M, Nollert G, Shahmohammadi M, et al. Prevention of hyperacute rejection by human decay accelerating factor in xenogeneic perfused working hearts. Transplantation 1996; 62: 729.
27. Houser SL, Kuwaki K, Knosalla C, et al. Thrombotic microangiopathy and graft arteriopathy in pig hearts following transplantation into baboons. Xenotransplantation 2004; 11: 416.
28. Lin SS, Weidner BC, Byrne GW, et al. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants. J Clin Invest 1998; 101: 1745.
29. Billingham ME. The postsurgical heart. The pathology of cardiac transplantation. Am J Cardiovasc Pathol 1988; 1: 319.
30. Fyfe B, Loh E, Winters GL, et al. Heart transplantation-associated perioperative ischemic myocardial injury. Morphological features and clinical significance. Circulation 1996; 93: 1133.
31. Turillazzi E, Baroldi G, Silver MD, et al. A systematic study of a myocardial lesion: Colliquative myocytolysis. Int J Cardiol 2005; 104: 152
32. Koonen DP, Glatz JF, Bonen A, et al. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim Biophys Acta 2005; 1736: 163.
33. Weaver JG, McGregor CG, Tazelaar HD, et al. Rejection severity directly correlates with myocyte apoptosis in pig-to-baboon cardiac xenotransplantation. J Heart Lung Transplant 2005; 24: 841.
34. Communal C, Sumandea M, de Tombe P, et al. Functional consequences of caspase activation in cardiac myocytes. Proc NatlAcadSciUSA2002; 99: 6252.
35. Byrne GW, Davies WR, Oi K, et al. Increased immunosuppression, not anticoagulation, extends cardiac xenograft survival. Transplantation 2006; 82: 1787.
36. Ezzelarab M, Garcia B, Azimzadeh A, et al. The innate immune response and activation of coagulation in alpha1,3- galactosyltransferase gene-knockout xenograft recipients. Transplantation 2009; 87: 805.
37. Diamond LE, Quinn CM, Martin MJ, et al. A human CD46 transgenic pig model system for the study of discordant xenotransplantation. Transplantation 2001; 71: 132.
38. Diamond LE, Byrne GW, Schwarz A, et al. Analysis of the control of the anti-Gal immune response in a non-human primate by galactose alpha-1-3 galactose trisaccharide-polyethylene glycol conjugate. Transplantation 2002; 73: 1780